We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03207178
Recruitment Status : Unknown
Verified June 2017 by Shanghai Longyao Biotechnology Inc., Ltd..
Recruitment status was:  Recruiting
First Posted : July 2, 2017
Last Update Posted : July 2, 2017
Xuzhou Medical University
Shanghai Jiao Tong University School of Medicine
Information provided by (Responsible Party):
Shanghai Longyao Biotechnology Inc., Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : February 28, 2019
Estimated Study Completion Date : February 28, 2020
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):